Intolerance to Tartrazine in Aspirin-Induced Asthma: Results of a Multicenter Study

Virchow, C; Szczeklik, A; Bianco, S.; Schmitz-Schumann, M; Juhl, E; Robuschi, M.; Damonte, Camilla; Menz, G; Serwońska, M

doi:10.1159/000195391

Cited by 34 publications

(11 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tartrazine has been frequently linked to different illnesses such as chronic urticaria (CU) and asthma [7][8][9][10][11][12]. In addition, cases of angioedema, of purpura, exacerbation of atopic dermatitis and gastrointestinal symptoms related to tartrazine have been reported [13][14][15][16].…”

Section: Discussionmentioning

confidence: 99%

Suspected tartrazine‐induced acute urticaria/angioedema is only rarely reproducible by oral rechallenge

Nettis

Colanardi

Ferrannini

et al. 2003

Clin Experimental Allergy

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Suspected tartrazine‐induced acute urticaria/angioedema is only rarely reproducible by oral rechallenge

Nettis

Colanardi

Ferrannini

et al. 2003

Clin Experimental Allergy

View full text Add to dashboard Cite

show abstract

“…• Challenge studies (Corder and Buckley, 1995;David, 1987;Devlin and David, 1992;GrzelewskaRzymowska et al, 1986;Hong et al, 1989;Jimenez-Aranda et al, 1996;Kemp and Schembri, 1985;Marques et al,1995;Montano and Orea, 1989;Morales et al, 1995;Rowe, 1988Rowe, ,1994Schulte-Korne et al, 1996;Timberlake et al, 1992;van Bever et al, 1989;Virchow et al, 1988;Wilson and Scott,1989) • Reviews (Collins-Williams, 1985;Simon, 1986;Wuthrich, 1993).…”

Section: Hypersensitivity and Intolerancementioning

confidence: 99%

Scientific Opinion on the re-evaluation Tartrazine (E 102)

Aguilar¹,

Charrondière²,

Dusemund³

et al. 2009

EFSA Journal

View full text Add to dashboard Cite

The Panel on Food Additives and Nutrient Sources added to Food provides a scientific opinion re-evaluating the safety of Tartrazine (E 102). Tartrazine has been previously evaluated by the Joint FAO/WHO Expert Committee on Food Additives (JECFA) in 1966 and the EU Scientific Committee for Food (SCF) in 1975 and. Both committees established an Acceptable Daily Intake (ADI) of 0-7.5 mg/kg bw/day. The Panel was not provided with a newly submitted dossier and based its evaluation on previous evaluations, additional literature that became available since then and the data available following a public call for data. New studies included a study by Sasaki et al. from 2002 reporting effects on nuclear DNA migration in the mouse in vivo Comet assay, a study by McCann et al. from 2007 that concluded that exposure to a mixture including Tartrazine resulted in increased hyperactivity in 3-year old and 8-to 9-year old children and studies on neurodevelopment by Tanaka. The Panel notes that Tartrazine was negative in long-term carcinogenicity studies and that the effects on nuclear DNA migration observed in the mouse in vivo Comet assay are not expected to result in carcinogenicity. The Panel also concurrs with the conclusion from a previous EFSA opinion on the McCann et al. study that the findings of the study cannot be used as a basis for altering the ADI, and additionally considered that the Tanaka study can also not be used as a basis for altering the ADI. The Panel concludes that the present database does not give reason to revise the ADI of 7.5 mg/kg bw/day. The Panel also concludes that at the maximum reported levels of use, refined intake estimates are below the ADI. The Panel concludes that Tartrazine appears to be able to elicit intolerance reactions in a small fraction of the exposed population.The Panel also notes that sensitive individuals may react to Tartrazine at dose levels within the ADI. Tartrazine, FD&C Yellow No. 5, E 102, CAS 1934-21-0, 3-carboxy-5-hydroxy-1-(4'-sulphophenyl Tartrazine consists essentially of 3-carboxy-5-hydroxy-1-(4'-sulphophenyl)-4-(4'-sulphophenylazo) pyrazole trisodium salt and subsidiary colouring matters together with sodium chloride and/or sodium sulphate as the principal uncoloured components. Tartrazine is described as the sodium salt. The calcium and the potassium salts are also permitted (Directive 2008/128/EC). KEY WORDSThe purity is specified as not less than 85 % total colouring matters, calculated as the sodium salt. The remaining 15 % may be accounted for by sodium chloride or sodium sulphate (but this is never mentioned explicitly), water insoluble matter not more than 0.2 %, subsidiary colouring matters not more than 1.0 % and organic compounds other than colouring matters with a total not more than 0.5 % (4-hydrazinobenzene sulphonic acid, 4-aminobenzene-1-sulphonic acid, 5-oxo-1-(4-sulphophenyl)-2-pyrazoline-3-carboxylic acid, 4,4′-diazoaminodi(benzene sulphonic acid), tetrahydroxysuccinic acid).The absorption, distribution, metabolism and excretion of Tar...

show abstract

“…According to results of various surveys, in some aspirin intolerant patients, tartrazine -a yellow azobenzene dye widely used for colouring drinks, foods, drugs and cosmetics -precipitated bronchoconstriction and other symptoms similar to those caused by analgesics with anti-COX activity at different rates [9,52,[54][55][56]. In the earlier studies, provocation with tartrazine in aspirin intolerant asthmatics caused bronchospasm at a rate of 7.5 -15% [9, 52,54].…”

Section: Paracetamol and Tartrazine Intolerancementioning

confidence: 99%

“…In the earlier studies, provocation with tartrazine in aspirin intolerant asthmatics caused bronchospasm at a rate of 7.5 -15% [9, 52,54]. However, recent studies showed a bronchospasm rate of 0 -2.6% after provocation with tartrazine in patients with aspirin intolerant asthma [55,56]. In the large series of studies conducted by Stevenson et al (involving 150 aspirin intolerant asthmatic patients), although the positive response rate after giving tartrazine at doses of 25 and 50 mg was 4%, the response rate was negative in all of them after repeating the test in a double-blind, placebo-controlled fashion [56].…”

Section: Paracetamol and Tartrazine Intolerancementioning

confidence: 99%

Paracetamol and asthma

Karakaya

Kalyoncu

2003

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

Paracetamol (acetaminophen) is one of the over-the-counter analgesics that is used frequently for the self-management of some of the common disorders. There seems to be two types of relations between paracetamol and asthma - paracetamol intolerance leading to bronchospasm in analgesic-induced asthmatics; and the relation between asthma and the amount and frequency of consumption of paracetamol. Paracetamol is generally recommended as one of the safer analgesics in both analgesic tolerant and intolerant asthmatics, without the fear of severe bronchospasm that aspirin and other non-steroidal anti-inflammatory drugs can induce in these patients. However, Paracetamol is reported to cross-react with aspirin at a rate of approximately 20-30% in a dose-dependent way. Therefore, it should not be recommended to analgesic intolerant asthmatics, without performing oral provocation tests to prove its safety. The possible association between the amount and frequency of paracetamol consumption and the prevalence and degree of asthma as suggested by some of the recent surveys, needs to be investigated further.

show abstract

Intolerance to Tartrazine in Aspirin-Induced Asthma: Results of a Multicenter Study

Cited by 34 publications

References 17 publications

Suspected tartrazine‐induced acute urticaria/angioedema is only rarely reproducible by oral rechallenge

Suspected tartrazine‐induced acute urticaria/angioedema is only rarely reproducible by oral rechallenge

Scientific Opinion on the re-evaluation Tartrazine (E 102)

Paracetamol and asthma

Contact Info

Product

Resources

About